Ruizhi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruizhi Wang has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Yueqing Peng
Institute for Genomic Medicine, Vagelos College of Physicians and Surgeons, Columbia University
4 shared publications - Lianyan Zhou
Teachers College, Columbia University , New York, NY 10027
2 shared publications Ai Yamamoto
Department of Neurology, Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University , New York, NY 10032
1 shared publicationAngie Maldonado Rodriguez
1 shared publicationAngie N Maldonado Rodriguez
Department of Neurology, Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University , New York, NY 10032
1 shared publication- Angie N. Maldonado Rodriguez
Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University
1 shared publication
Latest Publications
- 14 November 2026
- Published by Oxford University Press (OUP) in SLEEP
Repairing the disruption of protein homeostasis ameliorates REM sleep dysfunction in mouse models of Huntington’s disease
Although disruption of sleep behavior is prevalent across different neurodegenerative diseases, there is little understood about the molecular mechanisms that tie them together. To explore this relationship, we turned to the autosomal dominant disorder Huntington’s disease (HD), which shares many features common to more prevalent sporadic diseases, such as abnormal protein accumulation, early cognitive changes, and cell type specific degeneration. Moreover, HD patients suffer from sleep disruption, which precedes the appearance of core clinical features of the disease. We have previously found that upregulation of selective autophagy can prevent the aberrant protein accumulation that is typical of HD and other disorders. Thus, given the robust modeling of HD, we performed sleep analysis in the presence or absence of the upregulation of selective autophagy, to test the hypothesis that the proteinopathy significantly contributes to sleep dysfunction. We found that HD mice display rapid eye movement (REM) sleep impairments and protein aggregation in sleep-related regions including the nucleus accumbens and amygdala. Augmenting selective autophagy in the brain slowed aberrant protein accumulation and ameliorated REM sleep deficits in HD mice. Taken together, these data suggest that the disruption of protein homeostasis may play a key role in sleep dysfunction and disease.
- 14 November 2026
- Published by Oxford University Press (OUP) in SLEEP
Repairing the disruption of protein homeostasis ameliorates REM sleep dysfunction in mouse models of Huntington’s disease
Although disruption of sleep behavior is prevalent across different neurodegenerative diseases, there is little understood about the molecular mechanisms that tie them together. To explore this relationship, we turned to the autosomal dominant disorder Huntington’s disease (HD), which shares many features common to more prevalent sporadic diseases, such as abnormal protein accumulation, early cognitive changes, and cell type specific degeneration. Moreover, HD patients suffer from sleep disruption, which precedes the appearance of core clinical features of the disease. We have previously found that upregulation of selective autophagy can prevent the aberrant protein accumulation that is typical of HD and other disorders. Thus, given the robust modeling of HD, we performed sleep analysis in the presence or absence of the upregulation of selective autophagy, to test the hypothesis that the proteinopathy significantly contributes to sleep dysfunction. We found that HD mice display rapid eye movement (REM) sleep impairments and protein aggregation in sleep-related regions including the nucleus accumbens and amygdala. Augmenting selective autophagy in the brain slowed aberrant protein accumulation and ameliorated REM sleep deficits in HD mice. Taken together, these data suggest that the disruption of protein homeostasis may play a key role in sleep dysfunction and disease.
- Open Access
- 28 October 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Sleep-dependent DNA methylation remodeling in basolateral amygdala fear engrams
- 28 October 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Open AccessSleep-dependent DNA methylation remodeling in basolateral amygdala fear engrams
- Open Access
- 13 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A neuron type-specific microexon in Ank3/ankyrin-G modulates calcium activity and neuronal excitability
Recent studies have revealed many alternative exons differentially spliced across diverse neuron types in the mammalian brain, but their links to neuronal physiology remain unclear. Here we characterize a deeply conserved microexon E35a in Ank3 encoding ankyrin-G (AnkG), a multifaceted adaptor protein best known as a master organizer of the axon initial segment (AIS) and as a leading genetic risk factor for bipolar disorder. E35a is predominantly skipped in cortical glutamatergic neurons but included in cortical GABAergic neurons and cerebellar neurons, which is dictated by multiple neuronal splicing factors. In E35a-deletion mice we generated, interneurons show increased excitability and somatic Ca2+ activity, without disruption in AIS. Biochemical analyses suggest that E35a inclusion facilitates AnkG interaction with a protein complex involving inositol trisphosphate receptors (InsP3Rs) important for intracellular Ca2+ signaling. Alternative splicing therefore allows AnkG to modulate neuron type-specific excitability in addition to its ubiquitous pan-neuronal role in organizing the AIS.
- 13 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA neuron type-specific microexon in Ank3/ankyrin-G modulates calcium activity and neuronal excitability
Recent studies have revealed many alternative exons differentially spliced across diverse neuron types in the mammalian brain, but their links to neuronal physiology remain unclear. Here we characterize a deeply conserved microexon E35a in Ank3 encoding ankyrin-G (AnkG), a multifaceted adaptor protein best known as a master organizer of the axon initial segment (AIS) and as a leading genetic risk factor for bipolar disorder. E35a is predominantly skipped in cortical glutamatergic neurons but included in cortical GABAergic neurons and cerebellar neurons, which is dictated by multiple neuronal splicing factors. In E35a-deletion mice we generated, interneurons show increased excitability and somatic Ca2+ activity, without disruption in AIS. Biochemical analyses suggest that E35a inclusion facilitates AnkG interaction with a protein complex involving inositol trisphosphate receptors (InsP3Rs) important for intracellular Ca2+ signaling. Alternative splicing therefore allows AnkG to modulate neuron type-specific excitability in addition to its ubiquitous pan-neuronal role in organizing the AIS.
- Open Access
- 24 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (52)
Synchrony of neuromodulatory systems during NREM sleep
Neuromodulatory systems play an essential role in regulating brain states and functions. The canonical view is that the release of monoamines including norepinephrine (NE) and serotonin (5-HT) is high during wakefulness and attenuated during sleep, particularly during rapid eye movement (REM) sleep, whereas the cholinergic system is active during both wakefulness and REM sleep and quiescent during non–REM (NREM) sleep. Recent studies have revealed a slow and rhythmic release pattern of neuromodulators during NREM sleep that drives infraslow oscillation (ISO) (0.02 to 0.03 Hz) in the brain. A key question is whether/how the release of different neuromodulators during sleep is coordinated. In this study, we combined 2-site fiber photometry with electroencephalogram/electromyography recording to monitor the release of NE, 5-HT, and acetylcholine in the cortex and hippocampus during sleep and wake cycles. We found that the ISO of these neuromodulators is synchronized during NREM sleep. The synchrony between neuromodulatory systems increases in the oscillatory cycles leading to arousal. Furthermore, pharmacological inhibition of either the 5-HT or NE system eliminates the oscillation of other neuromodulators during NREM sleep. Optogenetic activation of 5-HT or NE neurons during NREM sleep induces the release of other neuromodulators in the absence of sleep-to-wake transitions. These results suggest that the rhythmic neuromodulator releases are highly coordinated in the brain. The synchrony among multiple neuromodulatory systems across brain regions provides a powerful neural mechanism to orchestrate sleep architecture and sleep-related neural processes.
- 24 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (52)
Open AccessSynchrony of neuromodulatory systems during NREM sleep
Neuromodulatory systems play an essential role in regulating brain states and functions. The canonical view is that the release of monoamines including norepinephrine (NE) and serotonin (5-HT) is high during wakefulness and attenuated during sleep, particularly during rapid eye movement (REM) sleep, whereas the cholinergic system is active during both wakefulness and REM sleep and quiescent during non–REM (NREM) sleep. Recent studies have revealed a slow and rhythmic release pattern of neuromodulators during NREM sleep that drives infraslow oscillation (ISO) (0.02 to 0.03 Hz) in the brain. A key question is whether/how the release of different neuromodulators during sleep is coordinated. In this study, we combined 2-site fiber photometry with electroencephalogram/electromyography recording to monitor the release of NE, 5-HT, and acetylcholine in the cortex and hippocampus during sleep and wake cycles. We found that the ISO of these neuromodulators is synchronized during NREM sleep. The synchrony between neuromodulatory systems increases in the oscillatory cycles leading to arousal. Furthermore, pharmacological inhibition of either the 5-HT or NE system eliminates the oscillation of other neuromodulators during NREM sleep. Optogenetic activation of 5-HT or NE neurons during NREM sleep induces the release of other neuromodulators in the absence of sleep-to-wake transitions. These results suggest that the rhythmic neuromodulator releases are highly coordinated in the brain. The synchrony among multiple neuromodulatory systems across brain regions provides a powerful neural mechanism to orchestrate sleep architecture and sleep-related neural processes.
- Open Access
Alternative Splicing and CaV‐Associated Channelopathies
Voltage‐gated calcium channels (VGCCs) are multi‐subunit ion channel proteins that control and regulate a wide array of physiological processes. Their dysfunction has been implicated in several neurological, cardiac, psychiatric, endocrine, oncogenic, and muscular disorders. The diverse and specialized cellular functions involving VGCC‐mediated calcium signaling stem from two primary mechanisms: differential and cell‐specific expression of pore‐forming (α1) and auxiliary subunit genes, and extensive alternative splicing of their pre‐mRNA. All the 10 α1‐encoding genes undergo alternative splicing to generate a wide array of cell‐specific CaV variants with distinct biophysical, pharmacological, and protein–protein interaction properties. This proteomic diversity and the associated cell‐specific expression signature of CaV splice variants are tightly regulated by trans‐acting splicing factors—RNA‐binding proteins that control the inclusion or skipping of alternatively spliced exons during post‐transcriptional pre‐mRNA processing. The discovery that several channelopathies are caused by aberrant splicing due to genetic mutations in either cis‐acting binding elements on the pre‐mRNA or in core splicing machinery components highlights the crucial role of alternative splicing in VGCC‐related pathologies. These insights have opened new therapeutic avenues, as targeting the alternative splicing of disease‐associated specific exons has recently emerged as a novel, promising treatment for neurodevelopmental disorders and channelopathies associated with splicing dysfunction.
Open AccessAlternative Splicing and CaV‐Associated Channelopathies
Voltage‐gated calcium channels (VGCCs) are multi‐subunit ion channel proteins that control and regulate a wide array of physiological processes. Their dysfunction has been implicated in several neurological, cardiac, psychiatric, endocrine, oncogenic, and muscular disorders. The diverse and specialized cellular functions involving VGCC‐mediated calcium signaling stem from two primary mechanisms: differential and cell‐specific expression of pore‐forming (α1) and auxiliary subunit genes, and extensive alternative splicing of their pre‐mRNA. All the 10 α1‐encoding genes undergo alternative splicing to generate a wide array of cell‐specific CaV variants with distinct biophysical, pharmacological, and protein–protein interaction properties. This proteomic diversity and the associated cell‐specific expression signature of CaV splice variants are tightly regulated by trans‐acting splicing factors—RNA‐binding proteins that control the inclusion or skipping of alternatively spliced exons during post‐transcriptional pre‐mRNA processing. The discovery that several channelopathies are caused by aberrant splicing due to genetic mutations in either cis‐acting binding elements on the pre‐mRNA or in core splicing machinery components highlights the crucial role of alternative splicing in VGCC‐related pathologies. These insights have opened new therapeutic avenues, as targeting the alternative splicing of disease‐associated specific exons has recently emerged as a novel, promising treatment for neurodevelopmental disorders and channelopathies associated with splicing dysfunction.